EU Commission approves Entyvio for both Ulcerative Colitis and Crohn's disease - Takeda Pharmaceuticals
Takeda Pharmaceuticals has announced that the European Commission (EC) has on 27 May 2014, granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active Ulcerative Colitis (UC) and adults with moderately to severely active Crohn�s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins